scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1012259497 |
P356 | DOI | 10.1038/SREP00436 |
P932 | PMC publication ID | 3365283 |
P698 | PubMed publication ID | 22666539 |
P5875 | ResearchGate publication ID | 225184828 |
P50 | author | Yuen Kwok-yung | Q8060280 |
Lei-Han Tang | Q60544483 | ||
Lei Shi | Q92859608 | ||
P2093 | author name string | Jian-Dong Huang | |
Bin Yu | |||
David K Smith | |||
Bo-Jian Zheng | |||
Mei Yang | |||
Xuefei Li | |||
Erwei Song | |||
Qinqin Jiang | |||
Yandan Yao | |||
P2860 | cites work | The ClosTron: Mutagenesis in Clostridium refined and streamlined. | Q50449586 |
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines | Q39513114 | ||
Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer | Q39760012 | ||
Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy | Q39966345 | ||
Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models | Q40133689 | ||
Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis | Q40149322 | ||
Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo | Q40171422 | ||
Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro | Q40318166 | ||
A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy | Q40323887 | ||
ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. | Q40552048 | ||
Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma | Q43161957 | ||
Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors | Q43661617 | ||
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice | Q43677697 | ||
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis | Q43918986 | ||
Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats | Q45859551 | ||
Influence of the environment on the [4Fe-4S]2+ to [2Fe-2S]2+ cluster switch in the transcriptional regulator FNR. | Q46814622 | ||
Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo | Q47992263 | ||
Containment of tumor-colonizing bacteria by host neutrophils | Q50062621 | ||
Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella | Q50078763 | ||
A set of recombineering plasmids for gram-negative bacteria | Q50080127 | ||
Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors | Q50102730 | ||
Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium | Q50120814 | ||
Tumor-targeted Salmonella as a novel anticancer vector | Q50133173 | ||
Combination bacteriolytic therapy for the treatment of experimental tumors | Q24555050 | ||
Translational regulation of gene expression by an anaerobically induced small non-coding RNA in Escherichia coli | Q24634637 | ||
Bacterial therapies: completing the cancer treatment toolbox | Q24646711 | ||
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit | Q28222502 | ||
Exploiting tumour hypoxia in cancer treatment | Q28264146 | ||
Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium | Q30491729 | ||
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma | Q33340438 | ||
Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha | Q33495169 | ||
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium | Q33756746 | ||
Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors | Q33898615 | ||
High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors | Q33920984 | ||
Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer | Q33925546 | ||
In vivo expression technology strategies: valuable tools for biotechnology. | Q34056559 | ||
Bacteria as tumour-targeting vectors | Q35215803 | ||
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer | Q35840470 | ||
Tumor hypoxia and cancer progression. | Q36185821 | ||
Clostridium spores as anti-tumour agents. | Q36405753 | ||
Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. | Q36495546 | ||
The use of clostridial spores for cancer treatment. | Q36565145 | ||
Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo | Q36611812 | ||
Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours | Q36656933 | ||
Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment | Q36756869 | ||
Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. | Q37001301 | ||
Salmonella-allies in the fight against cancer | Q37762990 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hypoxia | Q105688 |
Salmonella Typhimurium | Q166491 | ||
P304 | page(s) | 436 | |
P577 | publication date | 2012-06-01 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain | |
P478 | volume | 2 |
Q37594096 | 'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice. |
Q33989955 | A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity. |
Q52568531 | A microfluidic device for studying chemotaxis mechanism of bacterial cancer targeting. |
Q46922239 | Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy |
Q64124307 | Advances in bacterial cancer therapies using synthetic biology |
Q49705034 | An obligatory anaerobic Salmonella typhimurium strain redirects M2 macrophages to the M1 phenotype |
Q37201418 | Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors in mice |
Q91890842 | Bacteria-cancer interactions: bacteria-based cancer therapy |
Q90716178 | Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells |
Q45870726 | Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo |
Q91996390 | Bugs as Cancer Drugs: Challenges and Opportunities |
Q36611406 | Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer |
Q54213329 | Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. |
Q37059663 | Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct |
Q35984126 | Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma. |
Q57428850 | Leveraging Physiology for Precision Drug Delivery |
Q41471232 | Microwave ablation combined with attenuated Salmonella typhimurium for treating hepatocellular carcinoma in a rat model |
Q35871464 | Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model |
Q27015676 | Salmonella and cancer: from pathogens to therapeutics |
Q91743156 | Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy |
Q90618645 | Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy |
Q26748794 | Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy |
Q37146297 | Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system |
Q60907839 | Targeted inactivation of Salmonella Agona metabolic genes by group II introns and in vivo assessment of pathogenicity and anti-tumour activity in mouse model |
Q37225613 | Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential |
Q38812773 | Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy. |
Q38647098 | Treatment of Neuroblastoma with an Engineered "Obligate" Anaerobic Salmonella typhimurium Strain YB1. |
Q37355548 | Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis |
Q37457696 | Tumor-tropic endothelial colony forming cells (ECFCs) loaded with near-infrared sensitive Au nanoparticles: A "cellular stove" approach to the photoablation of melanoma. |
Q58599910 | Tumour-targeting bacteria engineered to fight cancer |
Search more.